Abstract
The initial binding of N-fluorenylacetamide (2- FAA) and its N-hydroxy metabolite N-hydroxy-N-2-fluorenylacet- amide (N-OH-2-FAA) within the hepatic genome and the effect of ingestion of a 2-FAA-containing (0.05% wt/wt) diet on this binding were examined in the male noninbred Sprague-Dawley rat. Ingestion of 2-FAA for 2 weeks reduced the amount of newly bound carcinogen up to 80%. The extent of this decrease was significantly greater in rats treated with a single injection of 2- FAA when compared to one of N-OH-2-FAA. The distribution of carcinogen within the genome was measured after fractionation of chromatin by DNase II digestion followed by selective MgCl2 precipitation. Two hours after a single injection of N-OH-2-FAA, the amount of carcinogen bound per milligram DNA in the presumed template-active chromatin fraction was 16 times that bound to DNA of the presumed template-repressed chromatin fraction. The amount bound to DNA in the nuclease-resistant chromatin was equal to that observed in the DNA of the presumed template-active fraction. Most (85%) of the total bound carcinogen was located on less than 25% of the total DNA. Evaluation of the amount of carcinogen bound to the N-2 or C-8 positions of guanine demonstrated a significant inverse correlation between the amount bound to a DNA fragment and the percent of that binding occurring at the N-2 position. DNA of the repressed chromatin fraction had the largest N-2/C-8 ratio when compared to the ratios seen in both the expressed chromatin and nuclease-resistant chromatin DNA. Pretreatment of rats with 2- FAA when compared to one of N-OH-2-FAA. The distribution of carcinogen within the genome was measured after fractionation of 66.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 667-672 |
| Number of pages | 6 |
| Journal | Journal of the National Cancer Institute |
| Volume | 66 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1981 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Factors influencing the binding of n-2-fluorenylacetamide to specific regions of the hepatic genome in vivo in rats. / Schwartz, Edward L.; Braselton, W. Emmett; Goodman, Jay I.
In: Journal of the National Cancer Institute, Vol. 66, No. 4, 1981, p. 667-672.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Factors influencing the binding of n-2-fluorenylacetamide to specific regions of the hepatic genome in vivo in rats
AU - Schwartz, Edward L.
AU - Braselton, W. Emmett
AU - Goodman, Jay I.
PY - 1981
Y1 - 1981
N2 - The initial binding of N-fluorenylacetamide (2- FAA) and its N-hydroxy metabolite N-hydroxy-N-2-fluorenylacet- amide (N-OH-2-FAA) within the hepatic genome and the effect of ingestion of a 2-FAA-containing (0.05% wt/wt) diet on this binding were examined in the male noninbred Sprague-Dawley rat. Ingestion of 2-FAA for 2 weeks reduced the amount of newly bound carcinogen up to 80%. The extent of this decrease was significantly greater in rats treated with a single injection of 2- FAA when compared to one of N-OH-2-FAA. The distribution of carcinogen within the genome was measured after fractionation of chromatin by DNase II digestion followed by selective MgCl2 precipitation. Two hours after a single injection of N-OH-2-FAA, the amount of carcinogen bound per milligram DNA in the presumed template-active chromatin fraction was 16 times that bound to DNA of the presumed template-repressed chromatin fraction. The amount bound to DNA in the nuclease-resistant chromatin was equal to that observed in the DNA of the presumed template-active fraction. Most (85%) of the total bound carcinogen was located on less than 25% of the total DNA. Evaluation of the amount of carcinogen bound to the N-2 or C-8 positions of guanine demonstrated a significant inverse correlation between the amount bound to a DNA fragment and the percent of that binding occurring at the N-2 position. DNA of the repressed chromatin fraction had the largest N-2/C-8 ratio when compared to the ratios seen in both the expressed chromatin and nuclease-resistant chromatin DNA. Pretreatment of rats with 2- FAA when compared to one of N-OH-2-FAA. The distribution of carcinogen within the genome was measured after fractionation of 66.
AB - The initial binding of N-fluorenylacetamide (2- FAA) and its N-hydroxy metabolite N-hydroxy-N-2-fluorenylacet- amide (N-OH-2-FAA) within the hepatic genome and the effect of ingestion of a 2-FAA-containing (0.05% wt/wt) diet on this binding were examined in the male noninbred Sprague-Dawley rat. Ingestion of 2-FAA for 2 weeks reduced the amount of newly bound carcinogen up to 80%. The extent of this decrease was significantly greater in rats treated with a single injection of 2- FAA when compared to one of N-OH-2-FAA. The distribution of carcinogen within the genome was measured after fractionation of chromatin by DNase II digestion followed by selective MgCl2 precipitation. Two hours after a single injection of N-OH-2-FAA, the amount of carcinogen bound per milligram DNA in the presumed template-active chromatin fraction was 16 times that bound to DNA of the presumed template-repressed chromatin fraction. The amount bound to DNA in the nuclease-resistant chromatin was equal to that observed in the DNA of the presumed template-active fraction. Most (85%) of the total bound carcinogen was located on less than 25% of the total DNA. Evaluation of the amount of carcinogen bound to the N-2 or C-8 positions of guanine demonstrated a significant inverse correlation between the amount bound to a DNA fragment and the percent of that binding occurring at the N-2 position. DNA of the repressed chromatin fraction had the largest N-2/C-8 ratio when compared to the ratios seen in both the expressed chromatin and nuclease-resistant chromatin DNA. Pretreatment of rats with 2- FAA when compared to one of N-OH-2-FAA. The distribution of carcinogen within the genome was measured after fractionation of 66.
UR - http://www.scopus.com/inward/record.url?scp=0019485284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019485284&partnerID=8YFLogxK
U2 - 10.1093/jnci/66.4.667
DO - 10.1093/jnci/66.4.667
M3 - Article
C2 - 6939914
AN - SCOPUS:0019485284
VL - 66
SP - 667
EP - 672
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 4
ER -